NEWTOWN, Pa.--(EON: Enhanced Online News)--Helius Medical Technologies, Inc. (TSX: HSM, OTCQB: HSDT) ("Helius"
or the "Company") is pleased to announce that
Virginia Commonwealth University (VCU) in Richmond, VA, has been
launched as the fifth site to provide services supporting Helius’
ongoing pivotal trial investigating PoNS™ Therapy for the treatment of
subjects with balance disorder resulting from mild to moderate Traumatic
Brain Injury (TBI). Clinical trial sites in the U.S. and Canada include
Oregon Health and Science University in Portland OR, Montreal
Neurofeedback Center in Montreal, QB, Orlando Regional Medical Center in
Orlando, FL and HealthTech Connex Inc. in Surrey, BC.

“VCU is a nationally respected institution with an extensive history of
research and innovation in medicine and particularly TBI. They are
optimally situated to serve a key population area, and we are excited
that they will be participating in our clinical trial investigating the
PoNS™ Therapy”

“VCU is a nationally respected institution with an extensive history of
research and innovation in medicine and particularly TBI. They are
optimally situated to serve a key population area, and we are excited
that they will be participating in our clinical trial investigating the
PoNS™ Therapy,” said Helius CEO, Phil Deschamps.

“The mission of the TBI programs at VCU is to improve the lives of
individuals with TBI through state-of-the-art clinical care and
innovative research, said principal investigator, Dr. William Walker.
“These patients often have balance problems which may not respond to
conventional therapies. We are pleased to join this important research
on a promising treatment to address this need.”

The Portable Neuromodulation Stimulator (PoNS™) is an investigational
non-invasive device designed to deliver neurostimulation through the
tongue. PoNS™ Therapy combines the use of the device with physical
therapy and is currently being evaluated in a multicenter clinical trial
for the treatment of balance disorder for subjects with mild to moderate
Traumatic Brain Injury.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on
neurological wellness. Helius seeks to develop, license and acquire
unique and non-invasive platform technologies that amplify the brain’s
ability to heal itself. Helius intends to file for FDA clearance for the
PoNS™ device. For more information, please visit www.heliusmedical.com.

About Virginia Commonwealth University

Virginia Commonwealth University is a major, urban public research
university with national and international rankings in sponsored
research. Located in downtown Richmond, VCU enrolls more than 31,000
students in 225 degree and certificate programs in the arts, sciences
and humanities. Seventy-nine of the programs are unique in Virginia,
many of them crossing the disciplines of VCU’s 13 schools and one
college. The VCU Health brand represents the health sciences schools of
VCU, the VCU Massey Cancer Center and the VCU Health System, which
comprises VCU Medical Center (the only academic medical center and Level
I trauma center in the region), Community Memorial Hospital, Children’s
Hospital of Richmond at VCU and Virginia Premier Health Plan. For more,
please visit www.vcu.edu and vcuhealth.org.

The Toronto Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical
facts and constitute forward-looking statements or forward-looking
information within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws (“forward-looking
statements”).

All statements other than statements of historical fact included in this
news release are forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include, among others,
statements regarding ongoing or planned clinical research, expected
future development timelines, regulatory approvals, business initiatives
and objectives and use of proceeds from financings or other business
initiatives.

Forward-looking statements are often identified by terms such as “will”,
“may”, “should”, “anticipate”, “expects” and similar expressions.

There can be no assurance that such statements will prove to be accurate
and actual results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include the failure of the Company to achieve its business objectives
and other risks detailed from time to time in the filings made by the
Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any
forward-looking statements may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from those
predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the control
of the Company. The reader is cautioned not to place undue reliance on
any forward-looking statement. Such information, although considered
reasonable by management at the time of preparation, may prove to be
incorrect and actual results may differ materially from those
anticipated. Forward-looking statements contained in this news release
are expressly qualified by this cautionary statement. Risks and
uncertainties about the Company’s business are more fully discussed in
the Company’s disclosure materials, including the short form prospectus
filed in connection with the Offering, its Annual Report on Form 10-K
filed with the United States Securities and Exchange Commission and the
Canadian securities regulators and which can be obtained from either at www.sec.gov
or www.sedar.com.

Recent Stories

NEWTOWN, Pa.--(EON: Enhanced Online News)--Helius announced today that it has been issued its first method patent that features claims directed to the use of the PoNS™ device for human performance ... more »

NEWTOWN, Pa.--(EON: Enhanced Online News)--Helius Medical Technologies, Inc. announced today that it has been issued two medical method patents that together further protect the intellectual proper... more »